Document is current
Any future updates will be listed below
-
Authors
Zhang, Qi https://orcid.org/0000-0002-6096-0690
Fu, Qihan
Shen, Yinan
Cao, Wanyue
Jin, Gaowei
Zhang, Yize
Wu, Jiangchao
Chen, Cao
Wang, Hongkan
Xu, Xingyuan
Sun, Ke
Xue, Xing
Bondanza, Attilio
Cao, Daisy
Chu, Nina
Durham, Nick
Cobbold, Mark
Farsaci, Benedetto
Giardino Torchia, Maria Letizia
Hao, Yixin
Hong, Yi
Huang, Jiaqi
Humphries, Michael
Jian, Qijie
Moody, Gordon
Stone, John
Sun, Lingyan
Tu, Eric
Wang, Fei
Wang, Fuzhe
Yang, Ye
Yao, Yihong
Zou, Andy
Bai, Xueli
Liang, Tingbo https://orcid.org/0000-0003-0143-3353
- License Information
-
More Information
Article History
Received: 12 February 2025
Accepted: 9 June 2026
First Online: 15 July 2026
Ethics
Competing interests: D.C., Y. Hao, Y. Hong, M.H., Q.J., L.S., Fei Wang, Fuzhe Wang and A.Z. are employees of Shanghai AbelZeta, Shanghai, China. Y. Yao and J.H. are employees of AbelZeta Pharma, Gaithersburg, MD, USA. A.B., M.L.G.T. and J.S. are employees of AstraZeneca, Cambridge, UK. N.D., B.F., N.C., G.M., E.T., Y. Yang and M.C. are employees of AstraZeneca, Gaithersburg, MD, USA. J.S. and M.C. hold shares in AstraZeneca. G.M. and M.L.G.T. are listed as inventors on a patent (PCT/EP2021/060622) filed by AstraZeneca AB, which pertains to compositions and methods for treating cancer using armoured CAR T cells. The other authors declare no competing interests.
